Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Ultragenyx Pharma (RARE) PT Raised to $68 at Jefferies; Reiterates Hold
May 8, 2017 7:29 AM EDTJefferies raised its price target on Ultragenyx Pharma (NASDAQ: RARE) to $68.00 (from $66.00) while maintaining a Hold rating. 1Q expenses consisted of $51.3M R&D vs. $48.0M estimates, and $18.7M G&A vs. $20.2M.
Following recently reported ph.III KRN23 results in adult... More
